For pharma, med-device and healthcare agencies
NICE said yes. Now get it into the guideline clinicians actually use.
Eolas holds the local guidelines used across 90%+ of UK acute NHS Trusts. So we're the only platform that can help a NICE recommendation become local practice faster, right where clinicians prescribe.
90%+
of UK acute NHS Trusts
340,000+
unique NHS users
~80%
of use on mobile, at the bedside
The problem
Approval isn't adoption.
A NICE TA starts a 90-day funding clock. But the prescription only happens once a local guideline or protocol is written, approved and found by the clinician at 4am.
That local step is where launches stall. Updates sit in someone's inbox for months, not because anyone disagrees with the evidence, but because drafting and circulating them to senior clinicians is slow, exposing work.
Most brand teams can't see this happening. A formulary listing on a website looks like coverage. It isn't, if the guideline clinicians open on the ward hasn't changed.
The gap between national approval and local practice is administrative, and it's measured in months of lost patients and lost revenue.
The pathway
From NICE approval to the prescription.
One continuous pathway, in seven steps.
Pre-launch
- 1
NICE TA published
National decision made
- 2
National price agreed
Commercial terms set
Local launch
- 3
ICB funding sign-off
90-day clock starts
- 4
Trust formulary listing
D&T committee decides
- 5
Local protocol written
Drafted, verified, signed
Where Eolas works
Activate
- 6
Prescriber awareness
Every eligible clinician knows
Where Eolas works
- 7
Sustained use
Prescribing in line with the pathway
Where Eolas works
Steps 5 to 7 are where launches slow down, and where no other channel can reach. Eolas is where the protocol lives, so we're there when it's written and there when it's used.
What we do
Three steps, one outcome.
1. See the gap
Guideline Intelligence
We show you, Trust by Trust, whether local guidelines reflect the NICE recommendation or are still out of date. Most teams find their real coverage is far lower than they thought.
2. Close the gap
Guideline Acceleration
When NICE guidance changes, we flag it to the local teams who own the affected guidelines, bring in the supporting evidence and make the update easy to draft and approve. We remove the admin, not the clinical judgement.
3. Activate at the point of care
Prescriber Awareness
Once the guideline is live, eligible clinicians meet it where they prescribe. Clearly attributed, ABPI-compliant brand and education content sits in the same app, next to the same guideline, at the same moment.
Then we measure it: opportunity to prescribe, local adoption acceleration, and pathway coverage ahead of launch, all grounded in your own epidemiology and sales data.
Guideline gap report
See where local guidelines haven't caught up.
Tell us the product. We'll show you where local guidelines across the NHS haven't caught up with NICE yet. Include the therapy area and NICE TA number in your message if you have them.
Why only Eolas
Not alongside clinical work. Inside it.
The only platform that holds the Trust's own guidance.
Clinicians don't choose to visit Eolas. It's where their guidelines are, so it's where they go.
Unlike a media channel, the outcome is measurable.
Guideline status, clinician awareness and engagement, reported on one dashboard.
A closed loop, for the first time.
NICE approval to local protocol to prescriber awareness, tracked end to end.
Built by doctors, not for advertisers.
Most competitors were designed to monetise pharma. Eolas was built for clinicians, which is exactly why they rely on it.
The evidence
Peer-reviewed proof of impact on prescribing.
100%
prescribing accuracy with Ask Eolas
47%
standard practice, unaided
1.9
number needed to treat
What clinicians find on Eolas changes what they prescribe. Waldock et al., npj Antimicrobials and Resistance, 2026.
Independence
How we protect clinical trust.
We accelerate the adoption of NICE-approved guidance. We never change what that guidance says.
Local clinical teams author and approve every guideline. Eolas never edits clinical content on a sponsor's behalf.
No sponsored content inside guidelines. Brand content is always clearly attributed and kept separate.
Verified health professionals only. Aggregate reporting only, with no clinician-level data.
Add-on: AI Visibility
If the answer doesn't mention you, you're not in the conversation.
We help make sure accurate, attributed reference information about your portfolio sits in a source that AI answer engines rely on.
51%
of healthcare searches return an AI overview (WebFX, 2025)
50-90%
of AI medical responses aren't fully supported by their sources (Wu et al., Nature Communications, 2025)
Start with one product and one NICE decision.
Tell us the therapy and the TA. In 30 minutes we'll show you where local adoption is stuck, and what closing that gap is worth.